This is not the most recent version of the article. View current version (26 JUN 2014)

Intervention Protocol

You have free access to this content

Different infusion durations for preventing platinum-induced hearing loss in children with cancer

  1. Jorrit W van As1,*,
  2. Henk van den Berg2,
  3. Elvira C van Dalen2

Editorial Group: Cochrane Childhood Cancer Group

Published Online: 17 DEC 2013

DOI: 10.1002/14651858.CD010885


How to Cite

van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD010885. DOI: 10.1002/14651858.CD010885.

Author Information

  1. 1

    Emma Children's Hospital / Academic Medical Center, c/o Cochrane Childhood Cancer Group, Amsterdam, Netherlands

  2. 2

    Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands

*Jorrit W van As, c/o Cochrane Childhood Cancer Group, Emma Children's Hospital / Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, Netherlands. Jorritvas@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 17 DEC 2013

SEARCH

This is not the most recent version of the article. View current version (26 JUN 2014)

References

Additional references

Bertolini 2004
  • Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. Journal of Pediatric Hematology/Oncology 2004;26(10):649-55.
Dean 2008
  • Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. Journal of Pediatric Hematology/Oncology 2008;30(2):130-4.
Eloxatin SPC
  • Eloxatin Summary of Product Characteristics. www.sanofi-aventis.co.uk/products/Eloxatin_SPC.pdf. Accessed March 2nd 2010.
Gallagher 1979
Gietema 2000
  • Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355(9209):1075-6.
Gregg 2004
Grewal 2010
  • Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010;125(4):e938-50.
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jenney 2005
  • Jenney MEM. Late effects of cancer treatment and current protective measures. In: Voûte PA, Barett A, Stevens MCG, Caron HN editor(s). Cancer in Children. 5th Edition. New York: Oxford University Press, 2005:123-37.
Knight 2005
  • Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology 2005;23(34):8588-96.
Kremer 2008
  • Kremer LCM, van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, issue Issue 3.
Langer 2013
Leahey 2012
Li 2004
McHaney 1983
Parmar 1998
Qaddoumi 2012
Reddel 1982
  • Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 1982;66(1):19-23.
Ross 2009
  • Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics 2009;41(12):1345-9.
Schell 1989
  • Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology 1989;7(6):754-60.
Skinner 2004
Van As 2012
  • Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009219.pub2]
Veal 2001
  • Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001;7(8):2205-12.